The stock of Indian pharmaceutical major Dr. Reddy's Laboratories recorded its deepest weekly plunge in three years. Investors reacted with panic following quality failures in the active ingredient of its generic weight-loss drug, forcing a supply delay.
~6%
Single-Day Stock Fall
Price After Fall (Jul 9): ₹1,271→~6%
📊 One chart explains it
Dr. Reddy's Stock Index Value (Rebased to 100)
Takeaway: The stock crashed sharply in the second week of July 2026 due to the semaglutide generic setback.
⏳ Time Machine
How today’s news fits into the bigger picture
10 years ago
Around 2016, Indian generic firms focused primarily on simple small-molecule tablets like cholesterol and blood pressure medications.
Last year
In 2025, generic drugmakers globally began filing applications for semaglutide alternatives as patents neared expiration.
Last month
The stock was trading near its peak as excitement built around its clinical trial pipeline.
Yesterday
Dr. Reddy's was seen as a key contender to democratize weight-loss drugs globally.
Today
The company posted its worst weekly loss in three years, losing billions in market cap over weight-loss drug delays.
What happens next?
The company will likely appeal the regulatory decisions or settle patent disputes by mid-2027 to revive its launch timeline.
Dr. Reddy's Laboratories faced its worst stock market rout in three years, losing billions in valuation after hitches emerged regarding its generic semaglutide candidate. Semaglutide is the active ingredient behind blockbuster obesity medications like Wegovy and Ozempic. The sell-off highlights how heavily investors have priced in the high-margin weight-loss pipeline. Launching complex generic drugs requires navigating complex intellectual property rules, and any delay can hand early-mover advantages to domestic or international rivals.
💭 If you're wondering…
It is an active chemical compound used to manage Type 2 diabetes and treat chronic obesity under popular global brand names.
Did this story help?
Official sources
Knowledge Chain — tap a concept